27 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast PeerView Press

    • Science

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Ken Fujioka, MD - Leveraging the Tools at Hand: Current Perspectives on Weight-Loss Pharmacotherapy for Obesity Management

    Ken Fujioka, MD - Leveraging the Tools at Hand: Current Perspectives on Weight-Loss Pharmacotherapy for Obesity Management

    Go online to PeerView.com/QTC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in obesity management discusses aspects of obesity management, including current recommendations, the role of weight-loss pharmacotherapies, evidence regarding current and emerging weight-loss pharmacotherapies, and patient-centered treatment approaches. Upon completion of this activity, participants should be better able to: Summarize current treatment recommendations, with rationale for the long-term use of weight-loss pharmacotherapy in the management of obesity as a chronic disease, Evaluate recent evidence regarding available and emerging weight-loss agents, including current data on efficacy, safety, and anticipated effects in the context of obesity pathophysiology, Incorporate weight-loss pharmacotherapy in personalized obesity management plans, based on disease status and patient characteristics and preferences, Use motivational techniques to engage and support individuals in obesity management.

    • 40 min
    • video
    Gregory W. Albers, MD - Large Hemispheric Infarction: Exploring the Latest Clinical Advances in the Diagnosis and Treatment

    Gregory W. Albers, MD - Large Hemispheric Infarction: Exploring the Latest Clinical Advances in the Diagnosis and Treatment

    Go online to PeerView.com/NDJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a stroke and vascular neurologist shares a patient case to provide clinical relevance and a practical exploration of the latest advances in the diagnosis and treatment of patients with a large hemispheric infarction (LHI). Upon completion of this activity, participants should be better able to: Apply current evidence-based guidelines to diagnose and treat patients with an LHI, Identify clinical characteristics associated with increased risk of cerebral edema in patients following an LHI, Summarize the benefits and limitations of current and emerging therapeutic strategies to prevent cerebral edema in patients following an LHI.

    • 31 min
    • video
    John B. Buse, MD, PhD - Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases

    John B. Buse, MD, PhD - Complex Cases in Contemporary Practice: Applying New Evidence for SGLT2 Inhibitors in the Management of Patients With Comorbid Cardiometabolic Diseases

    Go online to PeerView.com/KYQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and chronic kidney disease (CKD) have intersecting risk factors, and their prevalence has increased dramatically over the past several decades. Accumulating evidence has shown that SGLT2 inhibitors not only improve glycemic control but also potentially target other chronic diseases at the cardiorenal intersection, resulting in improved cardiovascular and renal endpoints for patients with or without T2DM. Revised treatment guidelines from leading endocrinology and cardiology societies prioritize SGLT2 inhibitors, especially in patients with T2DM and atherosclerotic CVD, heart failure, and/or CKD. In this activity, based on a recent live webcast, a multidisciplinary panel of experts reviews FDA-approved indications, treatment guidelines, and the accumulating evidence for SGLT2 inhibitors in comorbid cardiometabolic diseases. To integrate clinical evidence into practice, the experts also present complex patient cases to offer strategies for personalizing treatment plans and improving outcomes for patients with T2DM, heart failure, and CKD. Upon completion of this activity, participants should be able to: Recognize FDA-approved indications and the placement of SGLT2 inhibitors in current treatment guidelines, Summarize the proposed mechanism(s) supporting the therapeutic potential of SGLT2 inhibitors to target cardiorenal endpoints in patients with and without T2DM, Evaluate safety and efficacy results from clinical trials and real-world studies of SGLT2 inhibitors to optimize cardiorenal outcomes in patients with and without T2DM, Incorporate SGLT2 inhibitors, as appropriate, into the care of clinically complex patients with comorbid cardiovascular, renal, and/or metabolic diseases.

    • 1 hr 16 min
    • video
    Javed Butler, MD, MPH, MBA - Strategies for Increasing Recognition and Diagnosis of Patients With Heart Failure: Evaluating the Role of Natriuretic Peptides As Clinical Biomarkers

    Javed Butler, MD, MPH, MBA - Strategies for Increasing Recognition and Diagnosis of Patients With Heart Failure: Evaluating the Role of Natriuretic Peptides As Clinical Biomarkers

    Go online to PeerView.com/VCA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on heart failure discusses strategies for recognizing and diagnosing heart failure in patients, including the role of natriuretic peptides as clinical biomarkers. Upon completion of this activity, participants should be better able to: Review recommendations offered in current evidence-based guidelines intended to encourage early recognition and timely diagnosis of patients with heart failure, Apply diagnostic and therapeutic strategies using BNP and NT-proBNP as clinical biomarkers to guide the care of patients with heart failure, Evaluate evidence-based strategies for identifying and treating heart failure in patients with reduced ejection fraction.

    • 51 min
    • video
    Robin Lachmann, MD, PhD / Melissa Wasserstein, MD - Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency

    Robin Lachmann, MD, PhD / Melissa Wasserstein, MD - Assessing the Potential Role of Emerging Therapies in the Early Diagnosis and Optimal Management of Chronic Visceral Acid Sphingomyelinase Deficiency

    Go online to PeerView.com/NPH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Chronic visceral acid sphingomyelinase deficiency (ASMD), also referred to as Niemann-Pick disease type B, is a rare and progressive autosomal recessive lysosomal storage disorder that causes progressive accumulation of sphingomyelin and other lipids in tissues throughout the body and is associated with significant morbidity and reduced life expectancy. The diagnosis of chronic visceral ASMD is often delayed by months or years, because its complex signs and symptoms overlap with other diseases. In this activity, leading experts review current consensus recommendations for the diagnosis of ASMD in pediatric and adult patients. The faculty also review the latest safety, efficacy, and tolerability data on emerging therapies and explore patient cases to offer practical strategies on how to optimally manage patients with chronic visceral ASMD. Upon completion of this activity, participants should be better able to: Diagnose individuals with ASMD through the application of recent consensus recommendations, Cite available efficacy, safety, and tolerability data on emerging therapeutic modalities for the treatment of patients with ASMD, Examine the potential impact that ongoing clinical trials of emerging therapeutic approaches may have on the future treatment of patients with ASMD.

    • 1 hr 3 min
    • video
    Pablo F. Mora, MD, FACE, CDE - Go Get the Glucagon! Current and Emerging Options for Treating Severe Hypoglycemia

    Pablo F. Mora, MD, FACE, CDE - Go Get the Glucagon! Current and Emerging Options for Treating Severe Hypoglycemia

    Go online to PeerView.com/CBF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert endocrinologist and certified diabetes educator discusses current and emerging treatment options for severe hypoglycemia. Upon completion of this activity, participants should be better able to: Recognize the role of glucagon for the treatment of severe hypoglycemia in patients with diabetes, Teach individuals outside of the hospital setting how and when to use glucagon to treat severe hypoglycemia, Evaluate the efficacy, safety, and ease of use of current and emerging glucagon rescue treatments for severe hypoglycemia

    • 33 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerView Press